In anticipation of the 2013 Genitourinary Cancers Symposium, which begins February 14 in Orlando, Florida, ChemotherapyAdvisor.com Editorial Board member Dr. Neal Shore, MD, FACS, has recommended nine abstracts that are most significant in terms of clinical impact for the practicing oncologist.
Dr. Shore is Director, CPI, Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, South Carolina.
Abstract #5
General Poster Session A: Prostate Cancer; Oral Abstract Session A: Prostate Cancer (eQ&A)
Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy
Dana Rathkopf
Continue Reading
Abstract #6
General Poster Session A: Prostate Cancer; Oral Abstract Session A: Prostate Cancer (eQ&A)
Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor
Howard I. Scher
Abstract #7
General Poster Session A: Prostate Cancer; Oral Abstract Session A: Prostate Cancer (eQ&A)
ARN-509 in men with high-risk nonmetastatic castration-resistant prostate cancer (CRPC)
Matthew Raymond Smith
Abstract #11
General Poster Session A: Prostate Cancer
Updated analysis of radium-223 dichloride (Ra-223) impact on skeletal-related events (SRE) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase III randomized trial (ALSYMPCA)
Nicholas J. Vogelzang
Abstract #18
General Poster Session A: Prostate Cancer
Enzalutamide monotherapy: Phase II study results in patients with hormone-naive prostate cancer
Bertrand Tombal
Abstract #22
General Poster Session A: Prostate Cancer
Prognostic value of serum androgens, by ultrasensitive assay, in metastatic castration-resistant prostate cancer (mCRPC): Phase III trial data
Charles J. Ryan
Abstract #114
General Poster Session A: Prostate Cancer
A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) in metastatic castrate-resistant prostate cancer (mCRPC)
Eric Jay Small
Abstract #350
General Poster Session C: Renal Cancer
Overall survival results from a phase III study of tivozanib hydrochloride versus sorafenib in patients with renal cell carcinoma
Robert John Motzer
Abstract #306
General Poster Session B: Prostate, Penile, Urethral, and Testicular Cancer, and Urothelial Carcinoma
A multi-analyte assay for the noninvasive detection of bladder cancer
Makito Miyake
